| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b797ad3bbab6d1d3bebfb0ebaae7c5e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2020-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38798eb452681f23c301a7bdf07e41f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d321188458e8e554ade664c45291465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08e5df2533d3e7109fb7d172c0fea588
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5a85984cb91a09033af80e086511661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_958138c27a712875596b720c40a289c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bab9edc3421a540da15b0100b4e3f62 |
| publicationDate |
2021-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021024005-A1 |
| titleOfInvention |
Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma |
| abstract |
The present invention provides a monoamine oxidase B (MAO-B) inhibitor compound for use in the prevention or treatment of prostate carcinoma (PCa), wherein no selective MAO-A inhibitor compound is co-administered. In the use, other agents for the treatment of PCa is administered and/or radiotherapy is used for the treatment of PCa together with or alternately with the selective compound MAO-B. Another aspect of the invention is the use of a MAO-B inhibitor compound in the manufacture of a medicament for the treatment of PCa. |
| priorityDate |
2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |